Applied Spectral Imaging (ASI) Reveals Advanced FISH Solutions That Deliver Ultra-fast Imaging Analysis

PathFusion scanners for FISH, H&E and IHC imaging and analysis offer laboratories an all-in-one solution from scanning to reporting. In addition, the comprehensive pathology suite expedites more slide scanning volumes, improves diagnostic accuracy and optimizes the overall workflow process.

Applied Spectral Imaging Launches Two New Products for the Digital Pathology Market

The PathFusion system is a cutting-edge workflow solution, bridging the gap between Brightfield pathology and FISH. Combining microscope-based Whole Slide Imaging, industry-leading Tissue FISH applications and revolutionary digital tissue matching of FISH with H&E/IHC samples, it provides accurate and validated analysis for higher diagnostic confidence.

Applied Spectral Imaging announced today that its GenASIs applications comply with CE-IVD requirements with the IQFISH lung cancer panel on Dako Omnis of Agilent Technologies Inc.

CARLSBAD, California, january 11, 2017

Applied Spectral Imaging (ASI) announced today that its GenASIsTM applications comply with CE-IVD requirements under the European Directive on In Vitro Diagnostic Medical Devices, for automated analysis with the IQFISH lung cancer panel on Dako Omnis (comprising of ALK, ROS1, RET and MET IQFISH probes) of Agilent Technologies Inc. (NYSE: A).

This clearance delivers to pathology labs the best of both worlds – ASI’s unmatched workflow efficiencies and enhanced accuracy, with Agilent’s new high-quality IQFISH lung cancer panel. The result ensures optimal performance and standardization of FISH analysis, without compromising the laboratories’ certification standards.

“This latest CE-IVD conformity is evidence of our commitment to improve patient care. Laboratories can now have a fully optimized FISH workflow with greater image quality, that negates the time-consuming and costly need for internal validation,” said Limor Shiposh, chief executive officer of ASI. “Being recognized for our industry-leading FISH imaging platforms, ASI is proud to be the first to market imaging platforms that are CE-IVD conformed with Agilent’s new IQFISH lung cancer panel. We are certain that this solution will rapidly become the new gold standard for pathologists in Fluorescence-based molecular analysis”, Mrs. Shiposh added.

 

About ASI

ASI is a global leader in the development of imaging solutions, supporting fluorescent, brightfield and spectral image-acquisition, for various pathology tests, FISH and karyotyping.

The GenASIs™ automated imaging platforms for pathology and genetic analysis provide advanced diagnostic aids for pathologists and cytogeneticists, with reproducible and standardized results. GenASIs platforms support manual and automatic scanning for a wide range of workflows and applications, to best suit the needs, size and budget of any lab.

ASI’s GenASIs applications are FDA cleared for BandView, FISHView, CEP XY, UroVysion, ALK, HER2/neu FISH and IHC Family for: HER2, ER, PR and Ki67.

ASI serves clinical laboratories, life science companies and research institutions in over 50 countries.

 

For More Information Please Contact

Applied Spectral Imaging

Limor Gurevitch

Phone: +1 (760) 929-2840

E-mail: gurevitchl@spectral-imaging.com

www.spectral-imaging.com 

Agilent Technologies and Applied Spectral Imaging Announce Co-Marketing Agreement for Fluorescence In Situ Hybridization

Thursday, April 7, 2016
SANTA CLARA and CARLSBAD, Calif., April 7, 2016

Agilent Technologies Inc. (NYSE: A) and Applied Spectral Imaging (ASI) today announced they have entered into an agreement to jointly market ASI’s most advanced GenASIs imaging platforms and Agilent’s fluorescence in situ hybridization (FISH) products and solutions, including its Dako Omnis instrument for automated FISH sample processing.

This agreement is expected to bring to pathology labs the components for a fully automated, end-to-end FISH workflow.

“We are excited to work with ASI,” said Herman Verrelst, vice president and general manager of Agilent’s Genomics Solutions Division and Clinical Applications Division. “Difficulty of fluorescence-based molecular analysis has always been a major pain point for our customers. We anticipate that Agilent’s broad portfolio of FISH reagents and instruments, and ASI’s industry-leading computer-aided imaging solutions, will address such critical customer needs and enable laboratories to have a standardized, efficient and high-quality FISH workflow.”

“ASI is proud to partner with Agilent, a global leader in diagnostics that shares our main objective to make patient care better,” said Limor Shiposh, chief executive officer of ASI. “This agreement will position both companies to support customers in all stages of workflows.”

About ASI

ASI is a global leader in the development of imaging solutions, supporting fluorescent, brightfield and spectral image-acquisition, for karyotyping, FISH and various pathology tests.

The GenASIs automated imaging platforms for pathology and genetic analysis provide advanced diagnostic aids for pathologists and cytogeneticists, with reproducible and reliable results. GenASIs platforms can be used with any brand of brightfield or fluorescence microscope, and support manual and automatic scanning for a wide range of workflows and applications, to best suit the needs, size and budget of any lab.

ASI serves clinical laboratories, life science companies and research institutions in over 50 countries. Information about ASI is available at www.spectral-imaging.com.

About Agilent Technologies

Agilent Technologies Inc. (NYSE: A), a global leader in life sciences, diagnostics and applied chemical markets, is the premier laboratory partner for a better world. Agilent works with customers in more than 100 countries, providing instruments, software, services and consumables for the entire laboratory workflow. The company generated revenue of $4.04 billion in fiscal 2015 and employs about 12,000 people worldwide. Information about Agilent is available at www.agilent.com.

# # #

Contact:

Victoria Wadsworth-Hansen, Agilent

+1 408 553 2005

victoria.wadsworth-hansen@agilent.com

 

Applied Spectral Imaging

+1 800 611 3466

sales@spectral-imaging.com

ASI and ScreenCell Partner to Develop a Novel, Non-Invasive Prenatal Diagnosis Based on Circulating Fetal Cells

Wednesday, November 4, 2015

Partnership is intended to overcome limitations of existing methods, widening the range of genetic abnormalities that can be screened.

Carlsbad CA, US and Sarcelles, FRANCE – November 4, 2015– Applied Spectral Imaging and ScreenCell announced today that they have entered into a global partnership to develop a procedure enabling genetic analysis of trophoblastic fetal cells for prenatal diagnoses of genetic diseases.  The partnering leverages ASI’s most advanced automated imaging platforms supporting FISH, brightfield and unique spectral image acquisition and analysis for karyotyping and FISH, and ScreenCell’s proprietary method for isolating circulating fetal cells.

Prenatal diagnosis is routine across the world and is especially valuable for women at advanced maternal age and those with high risk for chromosomal abnormalities.  However, such diagnosis is often performed using invasive procedures, introducing the risk of complications for both the mother and fetus.  In recent years, non-invasive prenatal testing (NIPT) on circulating cell free fetal DNA (cffDNA) in the maternal blood has been introduced, a method that combines advantages of both lower risk and cell-based specificity, but also has serious limitations.

ASI and ScreenCell are partnering to develop a new and highly reliable procedure for NIPT which would resolve these limitations.  This will be achieved by successfully isolating and analyzing circulating fetal cells to enable accurate diagnosis for a much wider range of genetic abnormalities than currently available methods allow.

“Our expertise as a technology leader affords us excellent perspective on this rapidly advancing field of diagnostics.  ASI is uniquely positioned to offer ScreenCell unmatched experience and imaging capabilities”, said Limor Shiposh, ASI’s Chief Executive Officer.  “Adding ScreenCell’s method for non-invasive prenatal testing to our extensive imaging offering will allow us to offer our customers highly advanced Rare Cell detection and analysis, and we feel fortunate to be able to partner with ScreenCell on such an important project”, Mrs. Shiposh added.

“We see ASI as the ideal partner for advancing non-invasive prenatal diagnosis based on circulating fetal cells,” said David Znaty, Chief Executive Officer of ScreenCell.  “Our goal is to develop and introduce a new, low risk and high yield testing method that combines our great success in isolating Rare Circulating Cellstogether with the highly intelligent imaging and analysis capabilities provided by ASI’s advanced platforms.  We are very excited about developing such a comprehensive solution.”

– ### –

About Applied Spectral Imaging (ASI)

Founded in 1993, ASI is a global leader in the development of imaging solutions for pathology, cytogenetic, and life science research.

ASI’s GenASIs™ automated imaging platforms for pathology and genetic analysis provide advanced diagnostic aids for pathologists and cytogeneticists, with reproducible and reliable results. The GenASIs platform can be used with most brightfield or fluorescence microscopes and supports manual and automatic scanning for a wide range of workflows and applications, to best suit the needs, size and budget of any lab.

ASI’s applications are also US FDA cleared for BandView Karyotyping, FISHView, SpotScan (for CEP XY, UroVysion, ALK and HER2/neu FISH), and HiPath (for IHC Family: HER2, ER, PR and Ki67).

About ScreenCell

ScreenCell was founded with the objective of designing and producing a simple but revolutionary technique allowing the fast and effective isolation of Rare Circulating Cells, yielding high-quality cellular and molecular characterization.

ScreenCell has developed a full range of downstream technologies enabling the characterization of isolated cells (expression of markers, detection of genetic mutations and aneuploidy) and is a pioneer in Circulating Tumor Cell (CTC) technologies.

ScreenCell is dedicated to creating technologies enabling molecular pathology, cell culture and enumeration, and cytomorphology evaluation, and sells a full range of point-of-care devices for in vitro diagnostics (IVD) assays and platforms.

For More Information Contact:

Mrs. Limor Shiposh, Chief Executive Officer
Applied Spectral Imaging
Carlsbad California, US
Tel: +1 800-611-3466
sales@spectral-imaging.com

Mr. David Znaty, Chief Executive Officer
ScreenCell
Sarcelles, FRANCE
Tel. +33 (0)1 82 32 31 30
contact@screencell.com

 

Applied Spectral Imaging Receives China FDA Clearance for BandView® Advanced Imaging Solution

Thursday, October 1, 2015

BandView® cytogenetic imaging solution is cornerstone for pursuing additional CFDA clearances.

Carlsbad CA, US and Shanghai, China – October 1, 2015 – Applied Spectral Imaging (ASI) announced today that it has received clearance from the Food and Drug Administration of the Republic of China (CFDA) for ASI’s BandView®.

BandView® is the advanced karyotyping application which is part of ASI’s market-leading imaging platforms, providing enhanced diagnostics workflow and high performance for brightfield, fluorescent and hyperspectral specimens. BandView saves valuable time for medical clinicians and researchers by automating the segmentation of chromosomes, optimizing image quality, and bringing uniquely powerful tools for review, editing and analysis.

“ASI is committed to fully supporting our customers in China. Receipt of this clearance symbolizes a major business achievement for ASI and will assist us in advancing our objective to make Chinese patient care better”, said Limor Shiposh, ASI’s Chief Executive Officer. “This clearance is the cornerstone for pursuing additional CFDA clearances for ASI’s family of comprehensive computer-aided imaging solutions for cytogenetic, pathology and life science research.”

Will-Tek Electro-Optical Ltd, ASI’s distribution partner in Shanghai, played an instrumental role in receiving the CFDA clearance. This regulatory pathway will be used to offer laboratories and research institutions in China ASI’s new, advanced solutions for more efficient and cost-effective workflows.

“Our long-term goal is to maximize customer benefit and usage, while understanding our customers’ clinical needs and perspective,” said Xiao-Miao, Gong, CEO of Will-Tek. “Until today, we have maintained 100% operation and customer satisfaction with ASI products, which confirms ASI product utility and the capability of our service. This CFDA approval reiterates our strong commitment to our customers in China, which will lead to even greater success.”

Will-Tek has worked closely with ASI for over a decade, and currently promotes the complete range of ASI’s GenASIs™ platforms for enhancing cytogenetic and pathology workflows, from interactive to fully-automated scanning and analysis, including remote networking workflows.

– ### –

About Applied Spectral Imaging (ASI)

Founded in 1993, ASI is a global leader in the development of imaging solutions for pathology, cytogenetic, and life science research.

ASI’s GenASIs™ automated imaging platforms for pathology and genetic analysis provide advanced diagnostic aids for pathologists and cytogeneticists, with reproducible and reliable results. The GenASIs platform can be used with most brightfield or fluorescence microscopes and supports manual and automatic scanning for a wide range of workflows and applications, to best suit the needs, size and budget of any lab.

ASI’s applications are also US FDA cleared for BandView Karyotyping, FISHView, SpotScan (for CEP XY, UroVysion, ALK and HER2/neu FISH), and HiPath (for IHC Family: HER2, ER, PR and Ki67).

About Will-Tek Electro-Optical Ltd

Will-Tek Electro-Optical Ltd. is the leading scientific instrument company for cytogenetics and pathology in China. With a long-standing culture of stability and sincerity, Will-Tek offers clients the best products and services available together with highly professional standards and execution. With well-trained professionals are located in both Beijing and Shanghai as well as extended branches all over China, Will-Tek provides the best possible performance tailored to each customer. Working closely with ASI for more than a decade, Will-Tek has built up a large expert user base. Will-Tek is promoting GenASIs fully-automated scanning systems as a complete solution for karyotyping and cytogenetics workflow, including remote workflows via the Internet.

For More Information Contact:

 

Mr. Bob Rosenbaum

Applied Spectral Imaging

Carlsbad California, US

Tel: +1 800-611-3466

sales@spectral-imaging.com

www.spectral-imaging.com

 

Mr. Chris Chang

Will-Tek Electro-Optical Ltd.

Shanghai, China 201103

Tel: + 86 21 6406 4668

Fax: +86 21 5422 5188

will-tek@will-tek.com.cn

Applied Spectral Imaging Receives South Korean Ministry of Food and Drug Safety (MFDS) Clearance for GenASIs™ HiPath IHC Family for HER2, ER, PR and Ki67

Thursday, April 16, 2015

Clearance enables offering ASI advanced image capture and analysis platform to the South Korean hospitals and laboratories.

Carlsbad, CA – April 16, 2015 – Applied Spectral Imaging (ASI) announced today that it has received clearance from the South Korean Ministry of Food and Drug Safety (MFDS) for its GenASIs HiPath image capture and analysis platform. The South Korean market is a key market for ASI’s computer-aided imaging solutions for pathology, which help improve patient care.

“We are looking forward to leveraging this important clearance to offer our advanced image capture and analysis platform to the Korean population”, said Limor Shiposh, ASI’s Chief Executive Officer.

ASI’s GenASIs HiPath IHC Family is an advanced image analysis platform for IHC samples that integrates with existing lab microscopes and workflows, providing labs with a cost-effective solution for digital pathology. The platform is intended for use as an aid to pathologists in the semi-quantitative analysis and scoring of HER2, and qualitative analysis and scoring of Estrogen Receptor (ER) (SP1), Progesterone Receptor (PR) and Ki67 (30-9) proteins in formalin-fixed, paraffin-embedded breast cancer tissue.

“The South Korean market is a rapidly-growing market, and with the GenASIs HiPath, pathologists in South Korean’s hospitals and laboratories will now be able to use their own microscope and capture the relevant tumor regions with just one click, receiving immediate scoring and statistical analysis of the selected region of interest,” said Limor Shiposh, ASI’s Chief Executive Officer. “This clearance is the result of months of work and it is a valuable addition to our worldwide clearances portfolio for computerized clinical diagnostic aids covering both brightfield IHC and FISH probes”, Mrs. Shiposh added.

“The GenASIs HiPath is a superior diagnostic tool which assists pathologists with their analysis”, said Mr. Moo Yeol Yoon, President of SeongKohn Traders’ Corp., ASI’s distributor for the GenASIs HiPath in South Korea. “We are confident that the Korean market will be eager to take advantage of this advanced imaging option and we are excited to facilitate that process. The ASI GenASIs HiPath provides an unprecedented diagnostic practice for the local pathologists, which will advance patient care and assist our customers in improving workflow and achieving more accurate clinical results, efficiently and cost effectively.”

About ASI

ASI is a global leader in the development of imaging solutions for pathology, cytogenetic, and life science research.

The GenASIs automated imaging platforms for pathology and genetic analysis provide advanced diagnostic aids for pathologists and cytogeneticists, with reproducible and reliable results. GenASIs platform can be used with any brand of brightfield or fluorescence microscope, and supports manual and automatic scanning for a wide range of workflows and applications, to best suit the needs, size and budget of any lab.

The GenASIs platform is FDA cleared for BandView Karyotyping, FISHView, SpotScan for CEP XY, UroVysion, ALK and HER2/neu FISH, and HiPath for IHC Family: HER2, ER, PR and Ki67.

ASI serves clinical laboratories, life science companies and research institutions in over 50 countries, through direct sales and service personnel and its extensive worldwide distribution partners.

 

About SeongKohn Traders’ Corp.

SKT is specialized in the import and distribution of Histo/Cytopathology lab instruments, reagents, and consumables representing global pathology companies.

During the last 27 years, the company has contributed to the automation of the sample preparation and the introduction of liquid-based cytology and the renovation of autopsy suites in the local market.

SKT is also contributing to the facilitation of digital pathology solutions in addition to the conventional diagnostic practice and provides ‘digital slide web hosting service’ for the regular proficiency tests and slide conferences for the Korean Society of Pathologists (KSP) and the Korean Society for Cytopatholgists (KSC) and their sub-study groups and regional meetings, as well as other toxicology, dental, veterinary organizations.  www.digitalpathology.co.kr

*****

 

For More Information Please Contact –

Applied Spectral Imaging 

Phone: +1(800) 611-3466

E-mail: Sales@spectral-imaging.com

www.spectral-imaging.com 

 

SeongKohn Traders’ Corp.

Tel:  +82 2 540 3311

Fax: +82 2 540 6333

E-mail: myyoon@seongkohn.co.kr

Website: www.seongkohn.co.kr

www.digitalpathology.co.kr